Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
1(14%)
Results Posted
0%(0 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_1
2
29%
Ph phase_3
3
43%
Ph not_applicable
1
14%
Ph phase_4
1
14%

Phase Distribution

2

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 3Large-scale testing
3(42.9%)
Phase 4Post-market surveillance
1(14.3%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(5)
Terminated(1)

Detailed Status

Completed5
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (28.6%)
Phase 33 (42.9%)
Phase 41 (14.3%)
N/A1 (14.3%)

Trials by Status

terminated114%
recruiting114%
completed571%

Recent Activity

1 active trials
Showing 5 of 7
recruitingnot_applicable

A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

NCT05429970
terminatedphase_3

Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction

NCT03127592
completedphase_3

MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains

NCT01198834
completedphase_4

Etodolac and Post-bleaching Sensitivity

NCT02881619
completedphase_3

A Study to Verify the Efficacy of YM177 (Celecoxib) in Postoperative Pain Patients

NCT01118572
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT05429970Not Applicable

A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

Recruiting
NCT03127592Phase 3

Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction

Terminated
NCT01198834Phase 3

MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains

Completed
NCT02881619Phase 4

Etodolac and Post-bleaching Sensitivity

Completed
NCT01118572Phase 3

A Study to Verify the Efficacy of YM177 (Celecoxib) in Postoperative Pain Patients

Completed
NCT01749228Phase 1

Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fed Condition

Completed
NCT01746719Phase 1

Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fasting Condition

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7